Komori
Japan Animal Referral Medical Center (6039) · RiskMitigated

Dilution of Share Value from Stock Options

First written in FY2016. 18 of 30 entries say "Materialised", first in FY2017-Q1. Latest entry: FY2026.

30entries
11years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseMitigatedFY2024 – FY20262016: 220162017: 320172018: 420182019: 420192020: 420202021: 320212022: 220222023: 320232024: 320242025: 120252026: 12026
Same theme, other companies
Share Dilution from the Exercise of Stock OptionsA theme 417 companies write about · 418 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2017: 43 of 78 companies on the "Worse" side.

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 418 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026MitigatedAnnual report

    「Stock option plan details None applicable. … No interim diluted net income per share has been presented for the interim consolidated accounting period because no potential shares existed.」

    No share acquisition rights or similar instruments existed, and presentation of diluted earnings per share was no longer required, further reducing the dilution risk from stock options.
  2. FY2026-H1MitigatedAnnual report

    「Stock option plan details None applicable. … No interim diluted net income per share has been presented for the interim consolidated accounting period because no potential shares existed.」

    The company stated that there were no applicable stock option plans or other share acquisition rights, and did not present diluted earnings per share for the interim period because no potential shares existed. This indicates that the potential dilution exposure had further decreased.
  3. FY2025-H1MitigatedAnnual report

    「Stock option plan details None applicable. … 1 April 2024–30 September 2024 (Note) The exercise of share acquisition rights increased the total number of shares issued by 19,500, and increased share capital and capital reserve by ¥4,875 thousand each.」

    The exercise of share acquisition rights resulted in the issuance of 19,500 shares during the interim period, while the stock option plan details were stated as not applicable, further reducing the potential dilution exposure.
  4. FY2024MitigatedAnnual report

    「After exercise (Shares) End of previous consolidated fiscal year 62,000 Exercise 30,500 Expiration - Balance unexercised 31,500」

    During the consolidated fiscal year, 30,500 stock options were exercised, reducing the unexercised balance to 31,500. The exercise period is stated as ending on 31 May 2024.
  5. FY2024-Q3MaterialisedAnnual report

    「During the third quarter accounting period, 50,000 treasury shares were acquired pursuant to a resolution of the Board of Directors dated 21 December 2023, and 2,000 treasury shares were disposed of through the exercise of share acquisition rights. As a result, the number of treasury shares as of the end of the third quarter accounting period was 120,100.」

    The exercise of share acquisition rights resulted in the disposal of 2,000 treasury shares, and part of the potential shares associated with stock options has occurred through actual share disposal.
  6. FY2024-Q1MaterialisedAnnual report

    「During the first quarter accounting period, 5,500 treasury shares were disposed of through the exercise of share acquisition rights. As a result, the number of treasury shares as of the end of the first quarter accounting period was 95,600.」

    The exercise of share acquisition rights resulted in the disposal of 5,500 treasury shares, and part of the potential shares associated with stock options has occurred through actual share disposal.
  7. FY2023MitigatedAnnual report

    「At the end of the period, the number of potential shares attributable to stock options was 62,000, equivalent to 2.2% of the total number of shares issued at period-end. If these stock options are exercised, the value per share may be diluted.」

    The number of potential shares decreased from 70,500, or 2.9%, at the end of the previous fiscal year to 62,000, or 2.2%, reducing the potential dilution exposure.
  8. FY2023-Q3MaterialisedAnnual report

    「During the third quarter accounting period, 3,000 treasury shares were disposed of through the exercise of share acquisition rights. As a result, the number of treasury shares as of the end of the third quarter accounting period was 104,600.」

    The exercise of share acquisition rights resulted in the disposal of 3,000 treasury shares, and part of the potential shares associated with stock options has occurred through actual share disposal.
  9. FY2022MitigatedAnnual report

    「At the end of the period, the number of potential shares attributable to stock options was 70,500, equivalent to 2.9% of the total number of shares issued at period-end. If these stock options are exercised, the value per share may be diluted.」

    The number of potential shares decreased from 85,000, or 3.5%, at the end of the previous fiscal year to 70,500, or 2.9%. During the period, 14,500 shares were exercised, reducing the dilution exposure.
  10. FY2022-Q3MaterialisedAnnual report

    「In addition, 3,000 shares were disposed of through the exercise of share acquisition rights. As a result, the number of treasury shares as of the end of the third quarter accounting period was 55,100.」

    The exercise of share acquisition rights resulted in the disposal of 3,000 treasury shares, and part of the potential shares associated with stock options has occurred through actual share disposal.
  11. FY2022-Q1MaterialisedAnnual report

    「In addition, 500 treasury shares were disposed of through the exercise of share acquisition rights. As a result, the number of treasury shares as of the end of the first quarter accounting period was 55,100.」

    The exercise of share acquisition rights resulted in the disposal of 500 treasury shares, and part of the potential shares associated with stock options has occurred through actual share disposal.
  12. FY2021MitigatedAnnual report

    「At the end of the period, the number of potential shares attributable to stock options was 85,000, equivalent to 3.5% of the total number of shares issued at period-end.」

    The number of potential shares decreased from 109,000, or 4.5%, at the end of the previous fiscal year to 85,000, or 3.5%. Meanwhile, 22,000 shares were exercised during the period and 2,000 shares expired.
  13. FY2021-Q3MaterialisedAnnual report

    「During the third quarter accounting period, 3,500 treasury shares were disposed of through the exercise of share acquisition rights. As a result, the number of treasury shares as of the end of the third quarter accounting period was 63,500.」

    The exercise of share acquisition rights resulted in the disposal of 3,500 treasury shares, and part of the dilution from potential shares has occurred through actual share disposal.
  14. FY2021-Q2MaterialisedAnnual report

    「1 July 2020–30 September 2020 (Note) 500 Ordinary shares 2,436,200 125 385,500 125 285,500 (Note) This increase resulted from the exercise of share acquisition rights.」

    The exercise of share acquisition rights resulted in the issuance of 500 shares during the second quarter accounting period, and part of the dilution from potential shares has occurred through actual share issuance.
  15. FY2021-Q1MaterialisedAnnual report

    「1 April 2020–30 June 2020 (Note) 1 2,000 Ordinary shares 2,435,700 500 385,375 500 285,375 (Note) 1. This increase resulted from the exercise of share acquisition rights. 2. Between 1 July 2020 and 31 July 2020, the exercise of share acquisition rights increased the total number of shares issued by 500, and increased share capital and capital reserve by ¥125 thousand each.」

    The exercise of share acquisition rights resulted in the issuance of 2,000 shares during the quarter and a further 500 shares before the filing date. Part of the dilution from potential shares has occurred through actual share issuance.
  16. FY2020MitigatedAnnual report

    「At the end of the period, the number of potential shares attributable to stock options was 109,000, equivalent to 4.5% of the total number of shares issued at period-end. If these stock options are exercised, the value per share may be diluted.」

    The number of potential shares decreased from 121,000, or 5.0%, at the end of the previous fiscal year to 109,000, or 4.5%. Meanwhile, 12,000 shares were exercised during the period, and part of the dilution has occurred through actual share issuance.
  17. FY2020-Q3MaterialisedAnnual report

    「1 October 2019–31 December 2019 1,500 Ordinary shares 2,431,700 375 384,375 375 284,375 (Note) This increase resulted from the exercise of share acquisition rights.」

    The exercise of share acquisition rights resulted in the issuance of 1,500 shares during the third quarter accounting period, and part of the dilution from potential shares has occurred through actual share issuance.
  18. FY2020-Q2MaterialisedAnnual report

    「1 July 2019–30 September 2019 3,000 Ordinary shares 2,430,200 750 384,000 750 284,000 (Note) 1. This increase resulted from the exercise of share acquisition rights. 2. Between 1 October 2019 and 31 October 2019, the exercise of share acquisition rights increased the total number of shares issued by 1,000, and increased share capital and capital reserve by ¥250 thousand each.」

    The exercise of share acquisition rights resulted in the issuance of 3,000 shares during the quarter and a further 1,000 shares before the filing date. Part of the dilution from potential shares has occurred through actual share issuance.
  19. FY2020-Q1MaterialisedAnnual report

    「1 April 2019–30 June 2019 5,500 Ordinary shares 2,427,200 1,375 383,250 1,375 283,250 (Note) This increase resulted from the exercise of share acquisition rights.」

    The exercise of share acquisition rights resulted in the issuance of 5,500 shares during the first quarter accounting period, and part of the dilution from potential shares has occurred through actual share issuance.
  20. FY2019MitigatedAnnual report

    「At the end of the period, the number of potential shares attributable to stock options was 121,000, equivalent to 5.0% of the total number of shares issued at period-end. If these stock options are exercised, the value per share may be diluted.」

    The number of potential shares decreased from 133,200, or 5.5%, at the end of the previous fiscal year to 121,000, or 5.0%. The dilution risk itself remains.
  21. FY2019-Q3MaterialisedAnnual report

    「1 October 2018–31 December 2018 (Note) 2,200 Ordinary shares 2,419,700 550 381,375 550 281,375 (Note) This increase resulted from the exercise of share acquisition rights.」

    The exercise of share acquisition rights resulted in the issuance of 2,200 shares during the third quarter accounting period, and part of the dilution from potential shares has occurred through actual share issuance. quantified=true, materialized=true.
  22. FY2019-Q2MaterialisedAnnual report

    「1 July 2018–30 September 2018 5,000 (Note) 1. This increase resulted from the exercise of share acquisition rights. 2. Between 1 October 2018 and 31 October 2018, the exercise of share acquisition rights increased the total number of shares issued by 1,200, and increased share capital and capital reserve by ¥300 thousand each.」

    The exercise of share acquisition rights resulted in the issuance of 5,000 shares during the quarter and a further 1,200 shares before the filing date. Part of the dilution from potential shares has occurred through actual share issuance.
  23. FY2019-Q1MaterialisedAnnual report

    「Between 1 July 2018 and 31 July 2018, the exercise of share acquisition rights increased the total number of shares issued by 3,000, and increased share capital and capital reserve by ¥750 thousand each.」

    The exercise of share acquisition rights resulted in the issuance of 3,000 shares before the filing date. Part of the dilution from potential shares has occurred through actual share issuance. The articles of incorporation also show an increase of 3,000 shares during the quarter.
  24. FY2018MitigatedAnnual report

    「At the end of the period, the number of potential shares attributable to stock options was 133,200, equivalent to 5.5% of the total number of shares issued at period-end. If these stock options are exercised, the value per share may be diluted.」

    The number of potential shares decreased from the previously reported 168,500, or 7.2%, to 133,200, or 5.5%. During the period, 33,800 shares were exercised and 1,500 shares expired.
  25. FY2018-Q3MaterialisedAnnual report

    「1 October 2017–31 December 2017 (Note) 3,500 2,389,200 875 373,750 875 273,750 (Note) Increase due to the exercise of share acquisition rights.」

    During the third quarter, 3,500 shares were issued through the exercise of share acquisition rights, converting part of the dilution from potential shares into actual share issuance.
  26. FY2018-Q2MaterialisedAnnual report

    「Change in total number of issued shares (shares) 45,000 (Note 1) Increase due to the exercise of share acquisition rights. (Note 2) Increase due to the issuance of new shares as restricted stock compensation.」

    During the quarter, the number of shares increased by 45,000, including shares issued through the exercise of share acquisition rights. Part of the dilution from potential shares has materialised as actual share issuance.
  27. FY2018-Q1MaterialisedAnnual report

    「(Note) Between 1 July 2017 and 31 July 2017, the exercise of share acquisition rights increased the total number of issued shares by 4,500 and increased capital stock and capital surplus by ¥1.125 million each.」

    The exercise of share acquisition rights before the filing date resulted in the issuance of 4,500 shares, converting part of the dilution from potential shares into actual share issuance.
  28. FY2017MitigatedAnnual report

    「At the end of the current fiscal year, the number of potential shares from stock options was 168,500, equivalent to 7.2% of the total number of issued shares at the end of the fiscal year.」

    The number of potential shares decreased from the previously reported 187,000, or 8.0%, to 168,500, or 7.2%, reducing potential dilution exposure.
  29. FY2017-Q1MaterialisedAnnual report

    「On 5 August 2016, the exercise of share acquisition rights increased the total number of issued shares by 6,000, capital stock by ¥1.5 million and capital surplus by ¥1.5 million.」

    The exercise of share acquisition rights resulted in the issuance of 6,000 shares, converting part of the dilution risk from potential shares into actual share issuance.
  30. FY2016First statedAnnual report

    「As of the filing date, the number of potential shares from stock options was 187,000, equivalent to 8.0% of the total number of issued shares as of the filing date.」

    The disclosure states that the exercise of options and sales in the market could affect per-share value and the supply-demand balance.
Moved together

"Expansion and strengthening of the affiliated-hospital network" moved the same way as this thread, in the same document, in 11 of its 30 moves.

1111101098★123456
  1. ★This thread
  2. 1Expansion and strengthening of the affiliated-hospital network11×
  3. 2Developing and Securing Outstanding Talent11×
  4. 3Providing State-of-the-Art Veterinary Care and Achieving Qualitative Growth10×
  5. 4Expansion of secondary-care facilities in major cities nationwide10×
  6. 5High Dependence on Interest-Bearing Debt and Interest Rate and Refinancing Risks9×
  7. 6Peripheral Services Related to Veterinary Medicine and Development of an Integrated Platform8×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Japan Animal Referral Medical Center yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.